Granted Patent
B2
US 12,616,710 · App. 19/278,338 · Granted May 5, 2026
Topical compositions
Inventors:
Varsha Bhatt (Oakland, CA); Radhakrishnan Pillai (Santa Rosa, CA); Arturo Angel (Santa Rosa, CA)
Assignee:
BAUSCH HEALTH IRELAND LIMITED
A61K31/7056A61K8/22A61K8/345A61K8/4913A61K8/731A61K9/0014A61K9/06A61K31/192A61K31/327A61K47/02A61K47/10A61K47/32A61P17/10A61Q19/005
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.
Claims (11)
1 . A topical gel formulation comprising:
1.2 wt. % clindamycin phosphate;
3.1 wt. % benzoyl peroxide comprising a plurality of benzoyl peroxide particles;
0.15 wt. % adapalene comprising a plurality of adapalene particles;
a polyhydric alcohol selected from the group consisting of propylene glycol, ethoxydiglycol, glycerol, and combinations thereof;
a gelling agent selected from the group consisting of hydroxypropylcellulose, hydroxyethylcellulose, carboxyvinyl polymers, carboxyvinyl copolymers, polyacrylates, acrylate copolymers, acrylamide/sodium acryloyldimethyltaurate copolymers, methylcellulose, hydroxypropylmethylcellulose, xanthan gum, carrageenan gum, and combinations thereof; and
potassium hydroxide,
wherein the plurality of benzoyl peroxide particles and the plurality of adapalene particles are uniformly dispersed in the formulation.
2 . The topical gel formulation of claim 1 , wherein the potassium hydroxide is present in an amount to provide a pH of 5-6.
3 . The topical gel formulation of claim 1 , wherein the formulation is stable at room temperature for at least six weeks.
4 . The topical gel formulation of claim 1 , wherein the polyhydric alcohol is propylene glycol.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 3, 2026
From: BHATT, VARSHA; PILLAI, RADHAKRISHNAN; ANGEL, ARTURO
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 075338/0302 →
SECURITY INTEREST
Recorded Mar 30, 2026
From: BAUSCH HEALTH IRELAND LIMITED; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 074223/0753 →
U.S. PATENT SECURITY AGREEMENT
Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
SECURITY INTEREST
Recorded Oct 7, 2025
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 072495/0656 →
Continuity (6)
Provisional Application
62881836
· Aug 1, 2019
References Cited (90)
US 3535422A
· Cox et al.
· 1970
[cited by applicant]
US 4056611A
· Young
· 1977
[cited by applicant]
US 5445823A
· Hall et al.
· 1995
[cited by applicant]
US 5446028A
· Klein et al.
· 1995
[cited by applicant]
US 5733886A
· Baroody et al.
· 1998
[cited by applicant]
US 6117843A
· Baroody et al.
· 2000
[cited by applicant]
US 6387383B1
· Dow et al.
· 2002
[cited by applicant]
US 8158109B2
· Abram et al.
· 2012
[cited by applicant]
US 8288434B2
· Chang et al.
· 2012
[cited by applicant]
US 8445543B2
· Vernet et al.
· 2013
[cited by applicant]
US 8663699B2
· Chang et al.
· 2014
[cited by applicant]
US 8703820B2
· Graeber et al.
· 2014
[cited by applicant]
US 8729127B2
· Graeber et al.
· 2014
[cited by applicant]
US 8785420B2
· Vernet et al.
· 2014
[cited by applicant]
US 8809305B2
· Graeber et al.
· 2014
[cited by applicant]
US 8895070B2
· Chang et al.
· 2014
[cited by applicant]
US 8936800B2
· Orsoni et al.
· 2015
[cited by applicant]
US 9078870B2
· Chang et al.
· 2015
[cited by applicant]
US 9381179B2
· Graeber et al.
· 2016
[cited by applicant]
US 9387187B2
· Graeber et al.
· 2016
[cited by applicant]
US 9504704B2
· Chang et al.
· 2016
[cited by applicant]
US 9561208B2
· Chang et al.
· 2017
[cited by applicant]
US 9693988B2
· Chang et al.
· 2017
[cited by applicant]
US 9814690B2
· Orsoni et al.
· 2017
[cited by applicant]
US 20030170196A1
· Orsoni et al.
· 2003
[cited by applicant]
US 20040043946A1
· Popp
· 2004
[cited by applicant]
US 20050239723A1
· Amin et al.
· 2005
[cited by applicant]
US 20060204530A1
· Ramirez et al.
· 2006
[cited by applicant]
US 20070003585A1
· Clark
· 2007
[cited by examiner]
US 20090318371A1
· Ahumada Ayala
· 2009
[cited by applicant]
US 20100210571A1
· Popp
· 2010
[cited by applicant]
US 20160120797A1
· Rayudu
· 2016
[cited by applicant]
US 20180235924A1
· Toledano et al.
· 2018
[cited by applicant]
AU 2014216045A1
· 2016
[cited by applicant]
CN 102056481A
· 2009
[cited by applicant]
JP 2009500336A
· 2009
[cited by applicant]
JP 2011522820A
· 2011
[cited by applicant]
WO 1981000206A1
· 1981
[cited by applicant]
WO 1993020796A1
· 1993
[cited by applicant]
WO 1995031978A1
· 1995
[cited by applicant]
WO 2007002831A2
· 2007
[cited by applicant]
WO 2009148584A1
· 2009
[cited by applicant]
Office Action for corresponding Japanese Patent Application No. 2022-506666 dated Jun. 11, 2024, 6 pages.
[cited by applicant]
Office Action issued in corresponding Saudi Arabian Patent Application No. 522431568 dated Aug. 2, 2024, 7 pages, with English summary.
[cited by applicant]
Office Action issued in corresponding Chinese Patent Application No. 202080052185.4, dated Feb. 8, 2024, 23 pages, with English Translation.
[cited by applicant]
Kircik, L. “Synergy and Its Clinical Relevance in Topical Acne Therapy,” J Clin Aesthet Dermatol., vol. 4, No. 11, pp. 30-33 (2011).
[cited by applicant]
Leyden, J., “Antibiotic-Resistant Propionibacterium acnes Suppressed by a Benzoyl Peroxide Cleanser 6%,” Cutis., vol. 82, p. 417-421, (2008).
[cited by applicant]
Stein Gold et al., “Efficacy and Safety of a Fixed-Dose Clindamycin 1.2%, Benzoyl Peroxide 3.1 %, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combinati…
[cited by applicant]
Zaenglein et al., “Guidelines of Care for the Management of Acne Vulgaris,” J Am Acad Dermatol., vol. 74, p. 945-973, (2016).
[cited by applicant]
Bowman et al., “Comparison of Clindamycin/Benzoyl Peroxide, Tretinoin Plus 4. Clindamycin, and the Combination of Clindamycin/Benzoyl Peroxide and Tretinoin Plus Clindamycin in the Treatment of Acne Vulgaris: A Randomiz…
[cited by applicant]
“Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects with Acne,” Clinical Trial Identifier: NCT00713609, 10 pages, Webpage <https :/ /clinicaltrials.gov /ct2/show/study/NCT00713609?ter…
[cited by applicant]
Stein Gold et al., “Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 6. 1.2%, Benzoyl Peroxide 3.1 %, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase 11 Study of the First Triple-Combina…
[cited by applicant]
Zaenglein, A L., “Topical retinoids in the treatment of acne vulgaris,” Semin. Cutan. Med. Surg., vol. 27, No. 3, pp. 177-182, (2008).
[cited by applicant]
Office Action issued in corresponding Canadian Application No. 3,149,296, dated Dec. 13, 2023, 4 pages.
[cited by applicant]
Office Action issued in corresponding European Application No. 20750261.8, dated Nov. 14, 2023, 7 pages.
[cited by applicant]
Office Action issued in corresponding Russian Application No. 2022104310, dated Dec. 15, 2023, 12 pages.
[cited by applicant]
Benzaclin Gel—Uses, Side Effects, and More, WebMD. Found on the Internet 10.08.2017. The link to the Internet source: https://web. archive. org/web/20170810075357 /https://www.webmd.com/drugs/2/drug-20405/benzacl in-top…
[cited by applicant]
Office Action issued in corresponding Ukrainian Application No. a202200895, dated Feb. 19, 2024, 9 pages, with English translation.
[cited by applicant]
First Office Action issued in corresponding Mexican Application No. MX/a/2022/001138, dated Sep. 26, 2024, 13 pages, with English translation.
[cited by applicant]
Office Action issued in corresponding UAE Application No. P6000193/2022, dated Oct. 10, 2024, 10 pages.
[cited by applicant]
Office Action for corresponding Chinese Patent Application No. 202080052185.4, with English Translation, 16 pages dated on Jun. 13, 2025.
[cited by applicant]
Chellquist et al., Benzoyl Peroxide Solubility and Stability in Hydric Solvents, Pharm. Res. (1992), vol. 9, No. 10, 1341-46.
[cited by applicant]
Leyden, Therapy for Acne Vulgaris, N. Engl. J. Med. (1997), vol. 336, No. 16, 1156-62.
[cited by applicant]
Topical Acne Drug Products for Over-the-Counter Human Use; Tentative Final Monograph, Federal Register (1985), vol. 50, No. 10, 2172-82.
[cited by applicant]
Mills et al., Comparing 2.5%, 5%, and 10% Benzoyl Peroxide on Inflammatory Acne Vulgaris, Pharmacology and Therapeutics (1986), No. 10, 664-67.
[cited by applicant]
Thiboutot et al., Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study, J. Am. Acad. Dermatol., vol. 57, 791-99 (20…
[cited by applicant]
Pariser et al., Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1 % and benzoyl peroxide 2.5% for the treatment of acne vulgaris, J. Drugs Dermatol., vol. 6, No. 9, 899-905 (2007).
[cited by applicant]
Galderma Clinical Trial NGT00441415 (2007 Update) (“Galderma 2007”).
[cited by applicant]
Tanghetti, Combination Therapy is the Standard of Care, Cutis 2005 ;76 (suppl. 2):8-14.
[cited by applicant]
Dosik et al., Cumulative Irritancy Comparison of Topical Retinoid and Antimicrobial Combination Therapies, SKIN med (2006; 5 :219-23).
[cited by applicant]
Practice Guidelines. Acne Vulgaris: Treatment Guidelines from the AAD. American Family Physician. vol. 95, No. 11. Jun. 1, 2017.
[cited by applicant]
Dutil, Benzoyl Peroxide: Enhancing Antibiotic Efficacy in Acne Management, STL vol. 15 No. 10; Dec. 1, 2010.
[cited by applicant]
Percy H. Sanjana, Safety and Efficacy of Adapalene Gel 0.1 % in Acne Vulgaris: Results of a Post-Marketing Surveillance Study; Indian J. of Dermatology Venereology Leprology; vol. 69, issue: 4 , p. 277-280, 2003.
[cited by applicant]
Examination Report No. 1 issued in corresponding Australian Application No. 2020322173, dated Mar. 12, 2005, 3 pages.
[cited by applicant]
Second Office Action issued in corresponding Mexican Application No. MX/a/2022/001138, dated Apr. 14, 2025, 12 pages, with English summary.
[cited by applicant]
Office Action issued in corresponding Russian Application No. 2022104310, dated Feb. 2, 2025, with English summary, 13 pages.
[cited by applicant]
Communication issued in corresponding European Patent Application No. 20 750 261.8, dated Mar. 31, 2025, 6 pages.
[cited by applicant]
Office Action issued in corresponding Mexican Patent Application No. MX/a/2022/001138, dated Jul. 7, 2025, with English translation, 14 pages.
[cited by applicant]
Office Action issued in corresponding Colombian Patent Application No. NC2022/0002253, dated May 29, 2025, with English translation, 16 pages.
[cited by applicant]
Canadian Office Action for related Canadian Patent Application No. 3,149,296, dated Jul. 22, 2025, 4 pages.
[cited by applicant]
Bahrain Office Action for related Bahrain Patent Application No. 20220023, filed Sep. 18, 2025, 10 pages.
[cited by applicant]
Galderma Receives FDA Approval for New Convenient Pump Dispenser of Differin Gel, 0.3% for Treatment of Acne Vulgaris, GALDERMA, https://www.galderma.com/news/galdermareceives-fda-approval-new-convenient-pump-dispenser-…
[cited by applicant]
James Q. Del Rosso, Study Results of Benzoyl Peroxide 5%/Clindamycin 1% Topical Gel, Adapalene 0.1% Gel, and Use in Combination for Acne Vulgaris, 61. Drugs in Dermatology 616 (2007), 7 pages.
[cited by applicant]